SteriPlas penetrates biofilm, reaches around drivelines and surgical sites, and clears resistant bacteria1 to safeguard surgical recovery.
Surgical site infections blocking your patients’ recovery?
Damaged tissue, poor blood flow, and foreign bodies encourage bacterial growth and biofilm around drivelines and surgical sites.2,3
When healing stalls, risks escalate
Surgical site infection threatens the outcome of the entire procedure. Infection around surgical sites or drivelines stalls healing, delays recovery, and increases the risk of re-operation, implant removal, and sepsis.2,3
Standard therapies fail, allowing surgical site infections to persist
Despite best practice, many standard approaches can’t fully destroy bacteria in surgical sites, leaving infection to persist, and delay recovery.
Systemic antibiotics can’t reach poorly perfused tissue effectively.5,6
Topical therapies struggle to penetrate biofilm or irregular wound surfaces.5
Debridement may remove surface infection but risks further trauma.5
Protect recovery with
SteriPlas Premium Cold Plasma clears infection at its source.
Flowing into every microscopic space, it penetrates deep into tissue and around drivelines to destroy biofilm and resistant bacteria,1 without damaging surrounding healthy cells.6
It’s precise, painless, and proven when other therapies fall short.
Reduces bacterial load by 73.5%1
Accelerates healing7,8
Consistently outperforms antibiotics1
Discover SteriPlas
Getting started is simple
01
Speak to a representative to check eligibility
Meet with our team and check if you’re eligible to evaluate.
02
Start a fully supported evaluation
Get full training, clinical support, and outcome tracking throughout.
03
Choose to lease or buy
Decide on the best funding route for your hospital.
Clinically proven to clear infection
References
1. Isbary G, Heinlin J, Shimizu T, et al. Successful and safe use of 2 min cold atmospheric argon plasma in chronic wounds: results of a randomized controlled trial. Br J Dermatol. 2012;167(2):404-410. doi:10.1111/j.1365-2133.2012.10923.x
2. Patel CB, Blue L, Cagliostro B, et al. Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial. J Heart Lung Transplant. 2020;39(8):774-781. doi:10.1016/j.healun.2020.03.002
3. Taghavi S, Tandon D, Diamant AG, Masood MF, Balsara KR, Itoh A. Surgical Management of Driveline Infection in Continuous Flow Left Ventricular Assist Devices – The Journal of Heart and Lung Transplantation. 2016. Accessed September 22, 2025. https://www.jhltonline.org/article/S1053-2498(16)00393-4/fulltext
4. Jager NGL, van Hest RM, Lipman J, Roberts JA, Cotta MO. Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. Expert Rev Clin Pharmacol. 2019;12(7):623-634. doi:10.1080/17512433.2019.1621161
5. Stuermer EK, Plattfaut I, Dietrich M, et al. In vitro Activity of Antimicrobial Wound Dressings on P. aeruginosa Wound Biofilm. Front Microbiol. 2021;12. doi:10.3389/fmicb.2021.664030
6. Heinlin J, Isbary G, Stolz W, et al. Plasma applications in medicine with a special focus on dermatology: Plasma medicine. J Eur Acad Dermatol Venereol. 2011;25(1):1-11. doi:10.1111/j.1468-3083.2010.03702.x
7. Heinlin J, Zimmermann JL, Zeman F, et al. Randomized placebo-controlled human pilot study of cold atmospheric argon plasma on skin graft donor sites. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2013;21(6):800-807. doi:10.1111/wrr.12078
8. Isbary G, Stolz W, Shimizu T, et al. Cold atmospheric argon plasma treatment may accelerate wound healing in chronic wounds: Results of an open retrospective randomized controlled study in vivo. Clin Plasma Med. 2013;1(2):25-30. doi:10.1016/j.cpme.2013.06.001